Market Place
Sourcing Support
Ocugen Updates Business With Q4 And Full Year 2025 Financials
04 Mar 2026 //
GLOBENEWSWIRE
Ocugen Announces $20M Direct Offering of Stock and Warrants
08 Aug 2025 //
GLOBENEWSWIRE
Ocugen to Discuss Business Updates, Q2 2025 Results in August 1
17 Jul 2025 //
GLOBENEWSWIRE
Ocugen To Present at BIO International Convention 2025
11 Jun 2025 //
GLOBENEWSWIRE
Ocugen Updates on First Quarter 2025 Financials
09 May 2025 //
GLOBENEWSWIRE
Ocugen Provides Update with Q4 and Full Year 2024 Financial Results
05 Mar 2025 //
GLOBENEWSWIRE
Ocugen To Host Q4 & FY24 Results Call On March 5
21 Feb 2025 //
GLOBENEWSWIRE
Ocugen Provides Business Update with Q3 2024 Financial Results
08 Nov 2024 //
GLOBENEWSWIRE
Ocugen Announces Health Canada Approval for Phase 3 OCU400 Gene Therapy Trial
26 Aug 2024 //
GLOBENEWSWIRE
Ocugen Receives Health Canada Approval For OCU400 Phase 3 Trial
26 Aug 2024 //
GLOBENEWSWIRE
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
31 Jul 2024 //
GLOBENEWSWIRE
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
31 Jul 2024 //
GLOBENEWSWIRE
Ocugen To Host Q2 2024 Results Call On August 8
29 Jul 2024 //
GLOBENEWSWIRE
Ocugen Enrollment Approved for High Dose Cohort 3 in GARDian Study
21 Jun 2024 //
GLOBENEWSWIRE
Ocugen to Present at BIO International Convention 2024
29 May 2024 //
GLOBENEWSWIRE
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
28 May 2024 //
GLOBENEWSWIRE
Ocugen to Present at May 2024 Investor Conferences
10 May 2024 //
GLOBENEWSWIRE
Ocugen Distributing Series C Preferred To Common Holders
10 May 2024 //
GLOBENEWSWIRE
Ocugen To Host Q1 2024 Results, Business Updates Call On May 14
03 May 2024 //
GLOBENEWSWIRE
Ocugen At Noble Healthcare Virtual Conference
12 Apr 2024 //
GLOBENEWSWIRE
Ocugen to Host Conference Call to Provide Business & FY Updates
01 Apr 2024 //
GLOBENEWSWIRE
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
18 Mar 2024 //
GLOBENEWSWIRE
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy
13 Mar 2024 //
GLOBENEWSWIRE
Ocugen to Present at Investing in Cures Summit
06 Mar 2024 //
GLOBENEWSWIRE
Ocugen Clinical Showcase Webcast Now Available
28 Feb 2024 //
GLOBENEWSWIRE
Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit
26 Feb 2024 //
GLOBENEWSWIRE
Ocugen to Present at 2024 BIO CEO & Investor Conference
21 Feb 2024 //
GLOBENEWSWIRE
Ocugen to Present at Pharma Market Research Conference
31 Jan 2024 //
GLOBENEWSWIRE
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
16 Jan 2024 //
GLOBENEWSWIRE
Ocugen CEO to Present at NobleCon19 Noble Capital Markets™ Annual Conference
29 Nov 2023 //
GLOBENEWSWIRE
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit
07 Nov 2023 //
GLOBENEWSWIRE
Ocugen to Host Conference Call to Discuss Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
04 Oct 2023 //
GLOBENEWSWIRE
Ocugen to Participate in Fireside Chat at Chardan™s 7th Annual Conference
27 Sep 2023 //
GLOBENEWSWIRE
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
21 Sep 2023 //
GLOBENEWSWIRE
Ocugen to Participate in Panel at Cantor Fitzgerald Healthcare Conference 2023
20 Sep 2023 //
GLOBENEWSWIRE
Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
13 Sep 2023 //
GLOBENEWSWIRE
Ocugen Provides Business Update with Second Quarter 2023 Financial Results
21 Aug 2023 //
GLOBENEWSWIRE
Ocugen to Host Conference Call to Second Quarter 2023 Financial Results
18 Aug 2023 //
GLOBENEWSWIRE
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention & Scientific Assembly
30 Jun 2023 //
GLOBENEWSWIRE
Ocugen, Inc. Announces Business Advisory Board
05 Jun 2023 //
GLOBENEWSWIRE
Ocugen to Present at BIO International Convention 2023
23 May 2023 //
GLOBENEWSWIRE
Ocugen Provides Business Update with First Quarter 2023 Financial Results
05 May 2023 //
GLOBENEWSWIRE
Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect
26 Apr 2023 //
GLOBENEWSWIRE
Ocugen to Present at Association for Research in Vision and Ophthalmology 2023
20 Apr 2023 //
GLOBENEWSWIRE
Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023
11 Apr 2023 //
GLOBENEWSWIRE
Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference
07 Mar 2023 //
GLOBENEWSWIRE
Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer
06 Mar 2023 //
GLOBENEWSWIRE
Ocugen Provides Business Update with Q4 and Full Year 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
Ocugen Announces Submission of NDA to Initiate a PI Trial Evaluating OCU200
27 Feb 2023 //
GLOBENEWSWIRE
Ocugen to Present at Retinal Vascular Disease Drug Development Summit
17 Feb 2023 //
GLOBENEWSWIRE
Ocugen to Discuss Fourth Quarter and Full Year 2022 Financial Results
15 Feb 2023 //
GLOBENEWSWIRE
Ocugen Appoints Quan A. Vu as Chief Business Officer
01 Feb 2023 //
GLOBENEWSWIRE
Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
31 Jan 2023 //
GLOBENEWSWIRE
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
16 Dec 2022 //
GLOBENEWSWIRE
Ocugen Announces OCU400 Receives ODD for Retinitis Pigmentosa
15 Dec 2022 //
GLOBENEWSWIRE
Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell
13 Dec 2022 //
GLOBENEWSWIRE
Ocugen Announces Update on OCU400 Ph 1/2 Trial Targeting Retinitis Pigmentosa
07 Dec 2022 //
GLOBENEWSWIRE
Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
28 Nov 2022 //
GLOBENEWSWIRE
